SCHEMBL5157464

SCHEMBL5157464

O=c1[nH]c2ccc(C(F)(F)F)cc2c(-c2cc(Cl)ccc2O)c1Cc1ccc(O)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 10/20 0.74
CYP3A4 P08684 4/20 0.74
CYP2C19 P33261 4/20 0.74
CYP2D6 P10635 2/20 0.74
CYP1A2 P05177 1/20 0.74
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
ALDH1A1 P00352 1/20 0.48
MAPT P10636 1/20 0.48
BIRC5 O15392 1/20 0.43
EEF2K O00418 1/20 0.42
PLK4 O00444 1/20 0.42
IKBKB O14920 1/20 0.42
DYRK3 O43781 1/20 0.42
PIM1 P11309 1/20 0.42
CDK2 P24941 1/20 0.42
AKT1 P31749 1/20 0.42
AKT2 P31751 1/20 0.42
CLK2 P49760 1/20 0.42
GSK3B P49841 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5160635 0.92 CYP2C9 (0.78) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2
SCHEMBL5158929 0.88 CYP2C9 (0.86) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2
Bms-223131 SCHEMBL27618716 0.85 CYP2C9 (1.00) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2
Bms-223131 SCHEMBL3269828 0.85 CYP2C9 (1.00) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2
Bms-223131 SCHEMBL30627537 0.85 CYP2C9 (1.00) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2
SCHEMBL5159637 0.84 CYP2C9 (0.76) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2
SCHEMBL6106718 0.84 CYP2C9 (0.64) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2
SCHEMBL5159715 0.84 CYP2C9 (0.66) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2
SCHEMBL5157442 0.84 CYP2C9 (0.74) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2
SCHEMBL5159321 0.84 CYP2C9 (0.88) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1133474-B1 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS BRISTOL MYERS SQUIBB CO (US) 2007-02-21 EP claimed
EP-1133474-A4 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS BRISTOL MYERS SQUIBB CO (US) 2005-02-16 EP claimed
EP-1133474-A1 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2001-09-19 EP claimed
US-6184231-B1 NEUROPROTECTANTS; TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, TRAUMATIC BRAIN INJURY, SEXUAL DYSFUNCTION BRISTOL-MYERS SQUIBB 2001-02-06 US claimed
WO-2000034244-A1 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2000-06-15 WO claimed
EP-1133474-B1 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS BRISTOL MYERS SQUIBB CO (US) 2007-02-21 EP disclosed
EP-1133474-A4 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS BRISTOL MYERS SQUIBB CO (US) 2005-02-16 EP disclosed
CN-1129582-C 3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators BRISTOL MYERS SQUIBB CO (US) 2003-12-03 CN disclosed
CN-1329599-A 3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators BRISTOL MYERS SQUIBB CO (US) 2002-01-02 CN disclosed
EP-1133474-A1 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2001-09-19 EP disclosed
US-6184231-B1 NEUROPROTECTANTS; TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, TRAUMATIC BRAIN INJURY, SEXUAL DYSFUNCTION BRISTOL-MYERS SQUIBB 2001-02-06 US disclosed
WO-2000034244-A1 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2000-06-15 WO disclosed